Supplementary Materials

Supplementary Material for:

Type 1 diabetes immunotherapy using polyclonal regulatory T cells

Jeffrey A. Bluestone,* Jane H. Buckner, Mark Fitch, Stephen E. Gitelman, Shipra Gupta, Marc K. Hellerstein, Kevan C. Herold, Angela Lares, Michael R. Lee, Kelvin Li, Weihong Liu, S. Alice Long, Lisa M. Masiello, Vinh Nguyen, Amy L. Putnam, Mary Rieck, Peter H. Sayre, Qizhi Tang

*Corresponding author. E-mail: jeff.bluestone{at}ucsf.edu

Published 25 November 2015, Sci. Transl. Med. 7, 315ra189 (2015)
DOI: 10.1126/scitranslmed.aad4134

This PDF file includes:

  • Fig. S1. TCR repertoires of Tregs before and after expansion.
  • Fig. S2. Treg function of expanded Tregs from patients in phase 1 trial.
  • Fig. S3. Decreased CD56hi NK cells in circulation after Treg infusion.
  • Fig. S4. Direct evidence for expanded Tregs in the circulation after injection.
  • Fig. S5. Clearance of infused Tregs exhibits biphasic exponential decay kinetics.
  • Fig. S6. Gating strategies for cell sorting and analysis of unfixed CD4+ T cells and subsequent subsets.
  • Fig. S7. FACS-based phenotyping of nonexpanded and expanded FOXP3+ Treg.
  • Fig. S8. Equation for calculating “% of Total Tregs with Label”.
  • Table S1. Tabulation of cumulative number of adverse events for all cohorts categorized by system organ class and severity.
  • Table S2. Tabulation of cumulative number of adverse events categorized by cohort and severity.
  • Table S3. Listing of cumulative adverse events reported for cohort 1 by CTCAE term and severity.
  • Table S4. Listing of cumulative adverse events reported for cohort 2 by CTCAE term and severity.
  • Table S5. Listing of cumulative adverse events reported for cohort 3 by CTCAE term and severity.
  • Table S6. Listing of cumulative adverse events reported for cohort 4 by CTCAE term and severity.
  • Table S7. Two-phase decay model parameters.
  • Raw data for Fig. 2.
  • Raw data for Fig. 3B.
  • Raw data for Fig. 6.

[Download PDF]